The disclosure provides crystal form of OTR inhibitor and preparation method thereof. Specifically, the disclosure provides crystal form of 5-(3-(3-(6-Fluoronaphthalen-1-yl)azetidin-1-yl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridin and preparation method thereof. Compared with amorphous OTR inhibitor polymorphic OTR inhibitor has higher purity and better chemical stability, which is of great significance for the development of medicines suitable for industrial production and with good biological activity.本披露中提供了OTR抑制劑的晶型及其製備方法。具體而言，本披露中提供了化合物5-(3-(3-(6-氟萘-1-基)氮雜環丁烷-1-基)-5-(甲氧基甲基)-4H-1,2,4-三唑-4-基)-2-甲氧基吡啶的晶型及其製備方法。相對於無定型而言，多晶型的OTR抑制劑具有更高的純度，更為優異的化學穩定性，對開發適合工業生產且生物活性良好的藥物具有重要意義。
